On December 14, the CBN Capital Annual Conference and Capital Market Value List (CCV) Award Ceremony, the 2nd China (Macau) International High-quality Consumption Expo and Hengqin World Bay Area Forum were grandly held.
With the theme of "Embracing Change, Celebrating Innovation", the CBN Capital Annual Conference and Capital Market Value Index (CCV) Award Ceremony was held in Shanghai. The conference closely followed the trend of capital market reform, paid attention to the trajectory driven by scientific and technological innovation, grasped the new trend of industrial upgrading and capital empowerment, and explored new momentum for high-quality development. At the same time, the conference announced the annual list of the 202 CBN Capital Market Value List, and Shenzhen Yahuilong Biotechnology Co., Ltd. *** hereinafter referred to as "Yahuilong") was honored as the 2023 CBN Capital Market Value List of the Year Competitive Enterprise, and Wang Mingyang, secretary of the board of directors of Yahuilong, was invited to attend the meeting and receive the award.
The CBN Capital Market Value List focuses on the exploration of the high-quality development path of listed companies, takes corporate governance and risk resistance as the basic indicators, pays attention to innovation, competitiveness and influence, and adds a new return evaluation dimension to systematically analyze the development strength of listed companies in the whole market. Promoting the modernization of the industrial chain and the first chain, effectively driving the upstream and downstream collaborative co-creation, and promoting the optimization of industrial layout and structural adjustment are the selection criteria for the annual competitive enterprises in the CBN Capital Market Value List.
At the same time, Yahuilong won the 2023 In Vitro Diagnostic Industry Annual Excellent Case Annual Domestic Innovative Enterprise Award at the 2nd China (Macau) International High Quality Consumption Expo and Hengqin World Bay Area Forum.
As the cornerstone of precision medicine, in vitro diagnostics is one of the most promising areas in the medical device industry. At the same time, the emerging in vitro diagnostics market, represented by China, is growing rapidly. Driven by policy support, expansion of downstream market demand and technological progress, China's in vitro diagnostic industry has experienced rapid development, and the degree of industrialization has increased rapidly.
The 2023 In Vitro Diagnostics Industry High-Quality Development Forum will create industry influence from different perspectives of the industrial ecology. The 2023 In Vitro Diagnostics Industry Annual Outstanding Case Award released at this forum aims to encourage outstanding enterprises to play a leading role and promote industrial development. The awarding of this award is a recognition of Yahuilong's development strength and innovation ability, and will spur Yahuilong to insist on doing a good job in R&D and innovation, create more products with strong competitiveness, improve the menu of characteristic clinical diagnostic products, and realize the leap from narrowing the gap with foreign companies to gradually leading the industry, and continue to contribute to the high-quality development of the Greater Bay Area and the country.
Yahuilong was able to win two major awards, thanks to the company's rapid development momentum over the past year. In the first three quarters of 2023, Yahuilong achieved an operating income of 154.5 billion yuan, net profit attributable to the parent company of 28.5 billion yuan. Among them, the company's self-produced non-new crown business achieved operating income of 91.8 billion yuan, a year-on-year increase of 4791%, of which the self-produced chemiluminescence business and ** business revenue were 80.3 billion yuan, 27 billion yuan, a year-on-year increase. 77%。
For more than ten years, Yahuilong has relied on continuous product scientific and technological innovation and increased investment in scientific research to break the blockade and monopoly of overseas technology in the fierce market competition, and the company has today's industry competitiveness. In today's high-quality development, Yahuilong takes the corporate mission of "focusing on life and health and striving to make science and technology benefit mankind" as the driving force for continuous progress, and uses its strong scientific and technological research and development advantages and pioneering and enterprising innovation spirit to help the development process of China's in vitro diagnostic industry.
As the main force in the field of chemiluminescence, Yahuilong continues to increase investment in innovation, gradually realizes corner overtaking in characteristic fields, and gradually becomes a leader in domestic substitution in the field of in vitro diagnostics. In the future, Yahuilong will make persistent efforts, continue to adhere to innovation, promote the high-quality development of the company, effectively drive upstream and downstream collaborative co-creation, and contribute to the optimization of the layout and structural adjustment of the in vitro diagnostic industry.